## 1. Phylogeny

Cyclin‐dependent kinase 16 (CDK16), also known as PCTAIRE1 or PCTK1, occupies a phylogenetic niche distinct from canonical cell cycle regulators. Unlike classical CDKs that harbor the PSTAIRE motif in their αC helix, CDK16 is characterized by a non‐canonical PCTAIRE motif that plays a central role in its divergent regulation and substrate interactions (alonso2021caracterizacióndecdk1418 pages 114-118). This replacement is not simply a point mutation; rather, it signifies a broad evolutionary adaptation that accompanies unique N‐ and C‐terminal extensions found only in this subgroup. These extensions are absent in typical cell cycle kinases such as CDK1 and CDK2, and they contribute to specialized protein–protein interactions that underlie CDK16’s function in non‐proliferative, differentiated cells.

Phylogenetically, CDK16 is a member of the CMGC group of serine/threonine kinases—a clan that also includes mitogen-activated protein kinases (MAPKs), glycogen synthase kinases (GSKs), and several other CDK subfamilies. Within the CMGC ensemble, CDK16 is assigned to the atypical PCTAIRE subfamily, a grouping that also encompasses the closely related paralogs CDK17 and CDK18 (alonso2021caracterizacióndecdk1418 pages 29-32). Comparative sequence analyses have established that, although CDK16 maintains a moderate level (>50%) of sequence identity with kinases such as CDK5, it diverges in its regulatory sequences and domain extensions. This divergence appears to correlate with its specialized roles in post‐mitotic tissues, including the brain and testis, where processes such as vesicle-mediated trafficking and exocytosis rather than cell proliferation are of central importance (janackova2023mechanismusregulacecyklindependentní pages 92-95).

Moreover, orthologs of CDK16 have been identified across a diverse spectrum of metazoans, underscoring its evolutionary conservation in organisms that possess complex nervous systems and specialized secretory functions. The pattern of conservation and divergence suggests that the appearance of the PCTAIRE motif coincided with the evolution of advanced cellular functions, such as neurosecretion and the fine-tuning of vesicular dynamics. Thus, its evolutionary profile supports a scenario where CDK16 evolved from more canonical kinases to fulfill niche roles in differentiated tissues, thereby maintaining vital functions in neuronal signaling and spermatogenesis (alonso2021caracterizacióndecdk1418 pages 29-32, janackova2023mechanismusregulacecyklindependentní pages 92-95).

## 2. Reaction Catalyzed

CDK16 catalyzes a phosphorylation reaction typical of serine/threonine kinases. At its core, the enzyme facilitates the transfer of the gamma-phosphate from ATP to a hydroxyl group on specific serine or threonine residues within substrate proteins. The overall chemical reaction can be represented as:  
  ATP + [protein]–(L-serine/threonine) → ADP + [protein]–(L-serine/threonine)-phosphate + H⁺  
This reaction mechanism is highly conserved among kinases in the CMGC family and is central to their regulatory roles in cellular signaling (golkowski2020kinobeadlcmsphosphokinomeprofiling pages 1-3).

For CDK16, functional studies have highlighted that one of its primary substrates is NSF (N-ethylmaleimide sensitive factor), a protein critically involved in vesicle fusion events. Phosphorylation of NSF by CDK16 regulates its oligomerization, a structural reorganization necessary for the efficient docking and fusion of secretory vesicles with target membranes, thereby modulating exocytosis (dixonclarke2017structureandinhibitor pages 14-15).

In addition, in vitro evidence indicates that CDK16 phosphorylates cyclin Y (CCNY) at serine 336. While the full in vivo functional consequences of this modification are still being elucidated, phosphorylation of CCNY may play a role in stabilizing or modulating the assembly of the active CDK16-cyclin complex (alonso2021caracterizacióndecdk1418 pages 32-35, karimbayli2022dissectingtherolea pages 19-22). Thus, the phosphorylation reaction catalyzed by CDK16 not only conforms to the general chemical mechanism of ATP-dependent serine/threonine kinases but also exerts specialized control over cellular processes such as vesicle-mediated transport and hormone secretion.

## 3. Cofactor Requirements

The enzymatic activity of CDK16, like that of other serine/threonine kinases, critically depends on the presence of divalent metal ion cofactors. Magnesium (Mg²⁺) is particularly indispensable for CDK16’s catalytic efficiency. Mg²⁺ ions facilitate the correct binding and positioning of ATP within the active site by neutralizing the negative charges of the phosphate groups, thus enabling the efficient transfer of the gamma-phosphate (golkowski2020kinobeadlcmsphosphokinomeprofiling pages 1-3).

In typical reaction conditions, without Mg²⁺, the alignment of ATP in relation to the substrate’s serine or threonine residue is severely disrupted, leading to a marked decline in kinase activity. Although some protein kinases may employ manganese (Mn²⁺) as an alternative cofactor in vitro, there is substantial evidence to suggest that under physiological conditions, Mg²⁺ is the principal metal ion required for CDK16 function (golkowski2020kinobeadlcmsphosphokinomeprofiling pages 1-3, chowdhury2023cmgckinasesin pages 2-4).

No additional cofactors or specialized regulatory small molecules have been described for CDK16 beyond the requirement for Mg²⁺. The dependence on this ion is consistent with the catalytic paradigms established for the CMGC family and underscores the similarity in the fundamental chemistry of phosphoryl transfer reactions across serine/threonine kinases.

## 4. Substrate Specificity

CDK16 exhibits substrate specificity characteristic of CMGC family kinases, selectively phosphorylating serine/threonine residues on its target proteins. A prime example of its substrate recognition is its action on NSF. Phosphorylation of NSF by CDK16 modulates NSF oligomerization, subsequently influencing the efficiency of vesicle fusion during exocytosis processes. This modification ensures that vesicle docking occurs in a timely and spatially regulated fashion, thus supporting proper secretory function in neuronal cells and other tissues (dixonclarke2017structureandinhibitor pages 14-15, alonso2021caracterizacióndecdk1418 pages 114-118).

In addition to NSF, in vitro studies demonstrate that CDK16 can phosphorylate cyclin Y (CCNY) specifically at serine 336. Although the precise consensus sequence for CDK16 is not fully determined, its substrate recognition appears to be influenced by both linear amino acid sequences surrounding the phosphorylation site and by higher-order structural features that facilitate protein–protein docking (alonso2021caracterizacióndecdk1418 pages 32-35, karimbayli2022dissectingtherolea pages 19-22).

The substrate specificity is likely governed by the unique architecture of the kinase domain, particularly by the positioning of the conserved HRD and DFG motifs, as well as by the spatial presentation of the PCTAIRE motif. This motif is considered crucial for mediating interactions with noncanonical cyclins such as cyclin Y, thereby potentially contributing to substrate selection by orienting the catalytic machinery in a precise manner (dixonclarke2017structureandinhibitor pages 1-3, chowdhury2023cmgckinasesin pages 2-4).

While a definitive consensus phosphorylation motif for CDK16 has yet to be established in the literature extracted here, it is evident from its involvement in vesicle transport and exocytosis that its substrate selection is tailored to proteins involved in membrane dynamics and intracellular signaling. The combination of linear amino acid motifs in substrates together with tertiary structural elements likely dictates the recognition process, ensuring that phosphorylation occurs only on selected serine or threonine residues that are embedded in the correct structural context.

## 5. Structure

The structure of CDK16 is defined by a modular organization that is reminiscent of other protein kinases but with unique features that distinguish it from the classical cell cycle CDKs. At its core, CDK16 contains a catalytic kinase domain of approximately 300 amino acids that assumes the canonical bilobal architecture. The smaller N-terminal lobe is rich in β-sheets, while the larger C-terminal lobe is predominantly composed of α-helices. Within this catalytic core, key motifs—such as the HRD motif, which is indispensable for proton transfer and catalysis, and the DFG motif, which coordinates the binding of Mg²⁺ and ATP—are conserved (dixonclarke2017structureandinhibitor pages 1-3, golkowski2020kinobeadlcmsphosphokinomeprofiling pages 1-3).

A principal structural hallmark that sets CDK16 apart is the substitution of the classical PSTAIRE motif with a PCTAIRE motif located in the αC helix. This alteration is critical because it influences the kinase’s capacity to interact with its cyclin partners, primarily cyclin Y, and thereby modulates its activation status (alonso2021caracterizacióndecdk1418 pages 114-118). In addition to the central kinase domain, CDK16 features distinct N- and C-terminal extensions. Although these regions are not resolved in the available crystal structures—which predominantly cover the catalytic core—they are thought to play essential regulatory roles. For instance, residues within these extensions (notably within segments spanning approximately 112–121 in the N-terminus and 461–496 in the C-terminus) have been implicated in cyclin Y binding and in modulating subcellular localization (karimbayli2022dissectingtherolea pages 19-22, kamkar2015pftaire1(cyclindependent pages 49-53).

Crystal structure studies, predominantly focusing on the isolated kinase domain of CDK16, have revealed a degree of conformational plasticity. In complex with various inhibitors, the kinase domain can adopt distinct active or inactive conformations. Type I inhibitors, which compete with ATP, maintain the αC helix in a conformation that is compatible with active cyclin binding. In contrast, type II inhibitors tend to induce an inactive state by promoting a displacement or partial unfolding of the αC helix. Such adaptive structural features not only impact substrate recognition but also underscore the potential for the development of selective inhibitors that exploit the unique conformational dynamics of CDK16 (dixonclarke2017structureandinhibitor pages 13-14, dixonclarke2017structureandinhibitor pages 8-10).

Despite these advances, the full-length structure of CDK16, including its regulatory N- and C-terminal regions, remains unresolved by experimental methods. Deep-learning tools like AlphaFold are likely to complement crystallographic data by providing theoretical models that hypothesize the spatial organization of the terminal extensions; these regions may harbor motifs for binding 14-3-3 proteins or additional regulatory sequences critical for allosteric modulation. Overall, the structural designation of CDK16—comprising a highly conserved catalytic core with distinct noncanonical features, such as the PCTAIRE motif and unresolved regulatory extensions—highlights its dual role as a conventional serine/threonine kinase and as a driver of specialized cellular functions.

## 6. Regulation

The regulation of CDK16 is orchestrated by an intricate network of protein–protein interactions and post-translational modifications that ensure its activity is precisely tuned to the cellular context. At the forefront of this regulatory scheme is the interaction with cyclin partners. Cyclin Y (CCNY) and its homolog cyclin Y-like 1 (CCNYL1) bind to CDK16, and this association is indispensable for the enzyme’s activation and proper subcellular targeting. Specific regions within CDK16, particularly segments in the N-terminal portion (approximately residues 112–121) and the C-terminal extension (around residues 461–496), are critical for mediating these interactions (alonso2021caracterizacióndecdk1418 pages 29-32, karimbayli2022dissectingtherolea pages 19-22).

Phosphorylation represents a key post-translational modification regulating CDK16. One extensively characterized regulatory event is the phosphorylation of CDK16 at serine 153 by protein kinase A (PKA). This modification has been shown to reduce the affinity of CDK16 for cyclin Y, thereby acting as a negative feedback mechanism that restricts the formation of the active kinase–cyclin complex (janackova2023mechanismusregulacecyklindependentní pages 12-17, karimbayli2022dissectingtherolea pages 19-22). In parallel, phosphorylation events on cyclin Y itself are critical for robust complex formation and kinase activation. For instance, phosphorylation of cyclin Y at serine 336 has been documented in vitro, and additional modifications at serine residues such as serine 100 and serine 326 (the latter possibly mediated by AMPK under conditions of autophagic stimulation) have been implicated in further stabilizing and activating the CDK16–cyclin complex (alonso2021caracterizacióndecdk1418 pages 32-35, karimbayli2022dissectingtherolea pages 19-22).

In addition to phosphorylation and cyclin binding, the association with 14-3-3 adaptor proteins introduces another layer of regulation. 14-3-3 proteins typically bind phosphorylated serine/threonine motifs, and their interaction with either CDK16 or its cyclin partners can stabilize the active conformation of the kinase while also controlling subcellular localization—particularly at membranes where vesicle fusion events occur (dixonclarke2017structureandinhibitor pages 13-14, janackova2023mechanismusregulacecyklindependentní pages 92-95).

The conformational adaptability of the CDK16 kinase domain further contributes to its regulation. Inhibitor-binding studies have shown that the kinase domain can exist in multiple states, suggesting that allosteric mechanisms may allow the enzyme to rapidly respond to cellular signals. Such dynamic flexibility is essential in environments where rapid modulation of vesicle-mediated transport is necessary, and it may also provide a therapeutic window for the design of small molecules that target specific conformational states of CDK16. Together, these regulatory mechanisms—cyclin association, phosphorylation, 14-3-3 binding, and conformational shifting—ensure that CDK16 activity is tightly controlled to meet the precise needs of cells involved in secretion, neuronal signaling, and reproductive processes.

## 7. Function

CDK16 is a multifunctional serine/threonine protein kinase whose activity spans a wide spectrum of biological processes. One of its major roles is in the regulation of vesicle-mediated transport and exocytosis. In neuronal contexts, CDK16 modulates the release of growth hormone 1 (GH1) by phosphorylating substrates such as NSF. The phosphorylation of NSF alters its oligomerization state, thereby directly affecting the fusion of secretory vesicles with the plasma membrane—a process that is vital for both neurotransmission and hormone secretion (alonso2021caracterizacióndecdk1418 pages 114-118, dixonclarke2017structureandinhibitor pages 14-15).

The kinase’s role in vesicular trafficking is not restricted to neurons; it extends to specialized secretory cells involved in insulin secretion. In pancreatic β cells, the precise control of insulin granule exocytosis is critical for metabolic homeostasis, and CDK16’s ability to phosphorylate key proteins suggests it may influence the responsiveness of these cells to fluctuating blood glucose levels (alonso2021caracterizacióndecdk1418 pages 32-35).

Beyond vesicle fusion, CDK16 is indispensable for normal spermatogenesis. It is highly expressed in testicular tissue, and functional disruption of CDK16 leads to impaired sperm development. This defect is thought to arise from dysregulation of vesicular transport processes that are essential during the terminal differentiation of spermatocytes into mature spermatozoa (alonso2021caracterizacióndecdk1418 pages 114-118, karimbayli2022dissectingtheroleb pages 19-22).

Neurodevelopment is another arena where CDK16 functions prominently. It has been implicated in neuronal differentiation and dendritic development, likely through its regulation of cytoskeletal dynamics and vesicle trafficking that underpin neurite outgrowth. Alterations in CDK16 activity have been associated with changes in dendritic branching and synaptic plasticity, further indicating its role in shaping neural circuitry and possibly affecting learning and memory (janackova2023mechanismusregulacecyklindependentní pages 92-95, karimbayli2022dissectingtherolea pages 19-22).

In cancer biology, emerging evidence suggests that aberrant CDK16 activity may contribute to tumorigenesis. Misregulation of its substrate phosphorylation has been linked to enhanced cell proliferation and survival. For example, experimental data indicate that CDK16 can phosphorylate proteins involved in cell cycle control and apoptosis such as TP53 and PRC1—events that may promote cytoplasmic sequestration, prevent proper nuclear localization, or destabilize inhibitors of the cell cycle. These modifications, in turn, support malignant cell proliferation and resistance to therapy (karimbayli2022dissectingtherolea pages 19-22).

Taken together, the diverse biological roles of CDK16—ranging from vesicle-mediated exocytosis and hormone secretion in neurons to spermatogenesis and potential participation in oncogenic pathways—underscore its critical function as an integrator of signaling pathways in differentiated cells. Its evolutionary conservation and tissue-specific expression pattern further emphasize the importance of its precise regulation, ensuring that cellular processes such as neurotransmission, insulin secretion, and reproductive function proceed seamlessly.

## 8. Other Comments

Although there are presently no highly selective clinical inhibitors for CDK16, current research has begun to delineate its druggability, thereby opening new therapeutic avenues. Chemical proteomic studies have demonstrated that the ATP-binding pocket of CDK16 is accessible to small molecule inhibitors that can preferentially stabilize either the active (type I) or inactive (type II) kinase conformations (dixonclarke2017structureandinhibitor pages 13-14, jha2025deeplearningcoupledproximity pages 22-24). Such compounds, by disrupting the critical interactions between CDK16 and its regulatory partners (including cyclin Y and 14-3-3 proteins), offer promising leads for future drug development.

CDK16 has also garnered attention because of its associations with pathophysiological conditions. Altered expression or activity of CDK16 has been linked to neurodevelopmental disorders, potentially through its effects on neuronal differentiation and dendritic structure, as well as to reproductive deficiencies related to its essential role in spermatogenesis. In oncology, aberrant activation of CDK16 has been reported to favor tumor cell proliferation, survival, and resistance mechanisms via improper phosphorylation of key substrates; these findings suggest that CDK16 might serve as both a biomarker and a therapeutic target in certain malignancies (karimbayli2022dissectingtheroleb pages 19-22, alonso2021caracterizacióndecdk1418 pages 114-118).

Current research is focused on elucidating the complete structural organization of CDK16, including its currently unresolved N- and C-terminal extensions. Advanced computational approaches such as AlphaFold modeling are expected to enhance our understanding of these regions, which are likely to harbor novel regulatory motifs imperative for cyclin and 14-3-3 interactions. These insights will be critical for designing selective inhibitors that can modulate CDK16 activity with greater precision.

Furthermore, given the central role of CDK16 in coordinating vesicle-mediated transport processes, additional studies are warranted to explore its functions in metabolic regulation, neuronal communication, and endocrine signaling. Such investigations may reveal deeper mechanistic insights and establish new links between CDK16 dysregulation and broad disease spectrums including metabolic syndromes, neurodegenerative diseases, and cancer. Collectively, the body of research supporting CDK16’s multifaceted roles continues to expand, setting the stage for potential therapeutic exploitation in various clinical contexts.

## 9. References

1. alonso2021caracterizacióndecdk1418 pages 114-118
2. alonso2021caracterizacióndecdk1418 pages 29-32
3. alonso2021caracterizacióndecdk1418 pages 32-35
4. golkowski2020kinobeadlcmsphosphokinomeprofiling pages 1-3
5. chowdhury2023cmgckinasesin pages 2-4
6. dixonclarke2017structureandinhibitor pages 1-3
7. dixonclarke2017structureandinhibitor pages 13-14
8. dixonclarke2017structureandinhibitor pages 14-15
9. janackova2023mechanismusregulacecyklindependentní pages 12-17
10. janackova2023mechanismusregulacecyklindependentní pages 92-95
11. jha2025deeplearningcoupledproximity pages 22-24
12. karimbayli2022dissectingtherolea pages 19-22
13. karimbayli2022dissectingtherolea pages 16-19

References

1. (alonso2021caracterizacióndecdk1418 pages 114-118): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
2. (alonso2021caracterizacióndecdk1418 pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
3. (alonso2021caracterizacióndecdk1418 pages 32-35): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
4. (chowdhury2023cmgckinasesin pages 2-4): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
5. (dixonclarke2017structureandinhibitor pages 1-3): Sarah E. Dixon-Clarke, Saifeldin N. Shehata, Tobias Krojer, Timothy D. Sharpe, Frank von Delft, Kei Sakamoto, and Alex N. Bullock. Structure and inhibitor specificity of the pctaire-family kinase cdk16. Biochemical Journal, 474:699-713, Feb 2017. URL: https://doi.org/10.1042/bcj20160941, doi:10.1042/bcj20160941. This article has 45 citations and is from a domain leading peer-reviewed journal.
6. (dixonclarke2017structureandinhibitor pages 13-14): Sarah E. Dixon-Clarke, Saifeldin N. Shehata, Tobias Krojer, Timothy D. Sharpe, Frank von Delft, Kei Sakamoto, and Alex N. Bullock. Structure and inhibitor specificity of the pctaire-family kinase cdk16. Biochemical Journal, 474:699-713, Feb 2017. URL: https://doi.org/10.1042/bcj20160941, doi:10.1042/bcj20160941. This article has 45 citations and is from a domain leading peer-reviewed journal.
7. (dixonclarke2017structureandinhibitor pages 14-15): Sarah E. Dixon-Clarke, Saifeldin N. Shehata, Tobias Krojer, Timothy D. Sharpe, Frank von Delft, Kei Sakamoto, and Alex N. Bullock. Structure and inhibitor specificity of the pctaire-family kinase cdk16. Biochemical Journal, 474:699-713, Feb 2017. URL: https://doi.org/10.1042/bcj20160941, doi:10.1042/bcj20160941. This article has 45 citations and is from a domain leading peer-reviewed journal.
8. (dixonclarke2017structureandinhibitor pages 8-10): Sarah E. Dixon-Clarke, Saifeldin N. Shehata, Tobias Krojer, Timothy D. Sharpe, Frank von Delft, Kei Sakamoto, and Alex N. Bullock. Structure and inhibitor specificity of the pctaire-family kinase cdk16. Biochemical Journal, 474:699-713, Feb 2017. URL: https://doi.org/10.1042/bcj20160941, doi:10.1042/bcj20160941. This article has 45 citations and is from a domain leading peer-reviewed journal.
9. (golkowski2020kinobeadlcmsphosphokinomeprofiling pages 1-3): Martin Golkowski, Venkata Narayana Vidadala, Ho-Tak Lau, Anna Shoemaker, Masami Shimizu-Albergine, Joseph Beavo, Dustin J. Maly, and Shao-En Ong. Kinobead/lc-ms phosphokinome profiling enables rapid analyses of kinase-dependent cell signaling networks. Journal of Proteome Research, 19:1235-1247, Feb 2020. URL: https://doi.org/10.1021/acs.jproteome.9b00742, doi:10.1021/acs.jproteome.9b00742. This article has 13 citations and is from a peer-reviewed journal.
10. (janackova2023mechanismusregulacecyklindependentní pages 12-17): Z Janáčková. Mechanismus regulace cyklin-dependentní kinasy 16 prostřednictvím komplexu cyklin y/14-3-3. Unknown journal, 2023.
11. (janackova2023mechanismusregulacecyklindependentní pages 92-95): Z Janáčková. Mechanismus regulace cyklin-dependentní kinasy 16 prostřednictvím komplexu cyklin y/14-3-3. Unknown journal, 2023.
12. (jha2025deeplearningcoupledproximity pages 22-24): Kanchan Jha, Daichi Shonai, Aditya Parekh, Akiyoshi Uezu, Tomoyuki Fujiyama, Hikari Yamamoto, Pooja Parameswaran, Masashi Yanagisawa, Rohit Singh, and Scott H. Soderling. Deep learning-coupled proximity proteomics to deconvolve kinase signaling in vivo. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.27.650849, doi:10.1101/2025.04.27.650849. This article has 0 citations.
13. (kamkar2015pftaire1(cyclindependent pages 49-53): Fatemeh Kamkar. Pftaire1 (cyclin dependent kinase14): role and function in axonal outgrowth during the development of the cns. Unknown journal, 2015. URL: https://doi.org/10.20381/ruor-4143, doi:10.20381/ruor-4143. This article has 0 citations.
14. (karimbayli2022dissectingtherolea pages 16-19): J Karimbayli. Dissecting the role of cdk17 in epithelial ovarian cancer. Unknown journal, 2022.
15. (karimbayli2022dissectingtherolea pages 19-22): J Karimbayli. Dissecting the role of cdk17 in epithelial ovarian cancer. Unknown journal, 2022.
16. (karimbayli2022dissectingtheroleb pages 19-22): J Karimbayli. Dissecting the role of cdk17 in epithelial ovarian cancer. Unknown journal, 2022.